

Mycobacterium abscessus Complex Infections: A Retrospective Cohort Study

Maroun Sfeir,^{1,2} Marissa Walsh,³ Rossana Rosa,⁴ Laura Aragon,⁵ Sze Yan Liu,² Timothy Cleary,⁶ Marylee Worley,⁷ Corey Frederick,⁸ and Lilian M. Abbo⁹

¹Division of Infectious Disease, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital and ²Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, and ³Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, New York; ⁴Department of Medicine, UnityPoint Health, Iowa; and ⁵Department of Pharmacy and ⁶Department of Pathology, Jackson Memorial Hospital, ⁷Department of Pharmacy, Nova Southeastern University, ⁸Department of Pharmacy, Memorial Regional Hospital, and ⁹Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida

Background. Infections caused by *Mycobacterium abscessus* group strains are usually resistant to multiple antimicrobials and challenging to treat worldwide. We describe the risk factors, treatment, and clinical outcomes of patients in 2 large academic medical centers in the United States.

Methods. A retrospective cohort study of hospitalized adults with a positive culture for *M. abscessus* in Miami, Florida (January 1, 2011, to December 31, 2014). Demographics, comorbidities, the source of infection, antimicrobial susceptibilities, and clinical outcomes were analyzed. Early treatment failure was defined as death and/or infection relapse characterized either by persistent positive culture for *M. abscessus* within 12 weeks of treatment initiation and/or lack of radiographic improvement.

Results. One hundred eight patients were analyzed. The mean age was 50.81 ± 21.03 years, 57 (52.8%) were females, and 41 (38%) Hispanics. Eleven (10.2%) had end-stage renal disease, 34 (31.5%) were on immunosuppressive therapy, and 40% had chronic lung disease. Fifty-nine organisms (54.6%) were isolated in respiratory sources, 21 (19.4%) in blood, 10 (9.2%) skin and soft tissue, and 9 (8.3%) intra-abdominal. Antimicrobial susceptibility reports were available for 64 (59.3%) of the patients. Most of the isolates were susceptible to clarithromycin, amikacin, and tigecycline (93.8%, 93.8%, and 89.1%, respectively). None of the isolates were susceptible to trimethoprim/sulfamethoxazole, and only 1 (1.6%) was susceptible to ciprofloxacin. Thirty-six (33.3%) patients early failed treatment; of those, 17 (15.7%) died while hospitalized. On multivariate analysis, risk factors significantly associated with early treatment failure were disseminated infection (odds ratio [OR], 11.79; 95% confidence interval [CI], 1.53–81.69; *P* = .04), acute kidney injury (OR, 6.55; 95% CI, 2.4–31.25; *P* = .018), organ transplantation (OR, 2.37; 95% CI, 2.7–23.1; *P* = .005), immunosuppressive therapy (OR, 2.81; 95% CI, 1.6–21.4; *P* = .002), intravenous amikacin treatment (OR, 4.1; 95% CI, 0.9–21; *P* = .04), clarithromycin resistance (OR, 79.5; 95% CI, 6.2–3717.1, *P* < .001), and presence of prosthetic device (OR, 5.43; 95% CI, 1.57–18.81; *P* = .008). Receiving macrolide treatment was found to be protective against early treatment failure (OR, 0.13; 95% CI, 0.002–1.8; *P* = .04).

Conclusions. Our cohort of 108 *M. abscessus* complex isolates in Miami, Florida, showed an in-hospital mortality of 15.7%. Most infections were respiratory. Clarithromycin and amikacin were the most likely agents to be susceptible in vitro. Resistance to fluoroquinolone and trimethoprim/sulfamethoxazole was highly common. Macrolide resistance, immunosuppression, and renal disease were significantly associated with early treatment failure.

Keywords. *Mycobacterium abscessus*; infections; clinical outcome; treatment failure; epidemiology; erm gene.

Rapidly growing mycobacteria are ubiquitous environmental organisms increasingly recognized as important human pathogens [1–4]. The *Mycobacterium abscessus* complex is a species of rapidly growing mycobacteria first described by Moore and Frerichs in 1953 [5]. It was only in 1992, after its separation from the *Mycobacterium chelonae* group, that the *M. abscessus*

group strains acquired recognition as important human pathogens associated with significantly higher fatality rates than any other rapidly growing mycobacteria [5]. *M. abscessus* strains are responsible for a wide spectrum of infections in immunocompetent and immunocompromised hosts [2].

M. abscessus are usually found in water, soil, and dust and have been associated with infections after cosmetic and plastic surgery, invasive medical procedures employing contaminated equipment or material, and accidental injury where the wound is contaminated by soil [6]. Transplantation and cancer are also associated with *M. abscessus* group infections [6]. Isolates are usually resistant to multiple antimicrobials and are challenging to treat worldwide [7, 8]. Precise epidemiologic data are lacking, but as with other nontuberculous mycobacteria (NTM), prevalence seems to be increasing [1]. The advent of an aging population and an increase in the number of immunosuppressed

Received 8 May 2017; editorial decision 16 January 2018; accepted 24 January 2018.

Correspondence: L. Abbo, MD, University of Miami Miller School of Medicine, 1120 NW 14th St., Suite 851, Miami FL 33136 (labbo@med.miami.edu).

Open Forum Infectious Diseases®

© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy022

individuals suggest that the prevalence of NTM disease will increase [9]. A study by Adjemian et al. identified South Florida as a high-risk area for pulmonary nontuberculous mycobacterial disease [10]. Despite the increasing incidence of NTM infections including *M. abscessus*, data characterizing the clinical outcomes and risk factors for treatment failure are limited. We describe the risk factors, treatment, and clinical outcomes of patients in 2 large academic medical centers.

METHODS

This was a retrospective cohort study of hospitalized adults with a positive culture for *M. abscessus* group strains at Jackson Memorial Hospital (a 1558–licensed bed tertiary care teaching hospital) and the University of Miami Hospital (a 550–licensed bed academic and community hospital), both located in Miami, Florida, between January 1, 2011, and December 31, 2014. For the purpose of our study, not all *M. abscessus* isolates were subspeciated; therefore, all cultures are reported as *M. abscessus* group. A list of all adults who had a positive *M. abscessus* culture sent during the study period and who were admitted to 1 of the 2 tertiary care hospitals was obtained from the corresponding hospital microbiology laboratory records. Only patients with new *M. abscessus* complex infections diagnoses were included. Data were collected for patients' demographics, comorbidities, the source of infection, antimicrobial susceptibilities, antimicrobial therapy, immunosuppressive regimen, and clinical outcomes by retrospectively reviewing electronic medical records. When there were multiple positive cultures corresponding to a single or multiple episodes of infections from a single patient, only the first isolate of *M. abscessus* was included.

Currently, there is no consensus on the definition of treatment failure for *M. abscessus* complex infections. In this study, early treatment failure was defined as death and/or infection relapse characterized either by persistent positive culture for *M. abscessus* within 12 weeks of treatment initiation and/or lack of radiographic improvement. Mortality was defined as death related to infection with *M. abscessus* during a hospital stay or within 12 weeks of admission. Follow-up cultures and radiographs for all patients were evaluated within 12 weeks of *M. abscessus* treatment. Acute kidney injury was defined based on the Risk, Injury, Failure, Loss, End-Stage Renal Disease criteria [11]. Lung infection was defined according to the American Thoracic Society (ATS) bacteriological criteria as at least 2 positive expectorated sputum culture results or as a positive culture result from at least 1 bronchial wash or lavage or as a lung biopsy with mycobacterial histopathological features and positive culture [1], in addition to the presence of clinical respiratory symptoms, for example, unexplained cough or shortness of breath by other conditions, fever, etc. Skin and soft tissue infections were defined as positive skin or deep tissue cultures with clinical symptoms supportive of skin infection (eg,

purulent drainage, inflamed skin, etc.). Abdominal infections included positive intra-abdominal or peritoneal fluid cultures for *M. abscessus* with clinical documentation of intra-abdominal infection. Disseminated infection was defined as the presence of at least 2 sites of *M. abscessus* infection. Prosthetic devices were defined as the presence of permanently implanted artificial materials including heart pacemakers or defibrillators, bone prosthesis, and cosmetic implants. Only 1 isolate per patient was included for susceptibility testing, adopting the minimum inhibitory concentration (MIC) cutoffs from the Clinical and Laboratory Standards Institute (CLSI) guidelines [12]. Identification of *M. abscessus* isolates was performed at the Mycobacteriology Laboratory at the National Jewish Health in Denver, Colorado. The broth microdilution method with cation-supplemented Mueller-Hinton broth was used as recommended by the CLSI [12].

Duplicate patient records, patients aged <18 years, cultures reported as *M. abscessus/chelonae*, cases with missing clinical notes and/or laboratory data in the electronic medical record, and patients who did not meet the ATS definition criteria for *M. abscessus* lung infection were all excluded (Figure 1). For statistical analysis, data were collected, pooled, and analyzed using SPSS version 16.0 (SPSS, Chicago, IL). The χ^2 test was used for comparing categorical variables between groups, except when expected values within cells were <5, in which case the Fisher exact test was used. A *P* value <.05 was considered to indicate statistical significance. If significance was found, then subsequent multivariate analyses were performed using multiple logistic regression models.

The study was approved by the institutional review boards of the University of Miami and Jackson Health System.




Figure 1. Study design and inclusion and exclusion criteria. Abbreviations: ATS, American Thoracic Society; NTM, nontuberculous mycobacteria.

RESULTS

Two-hundred thirty-seven unique adult patients had a positive culture with *M. abscessus* complex, and 108 were included in the analysis (Figure 1). We excluded 49 duplicate cases, 16 pediatric cases, 15 cultures reported as *M. abscessus/M. chelonae*, 5 cases with missing clinical/laboratory data, and 44 patients who did not meet the ATS definition criteria for *M. abscessus* lung infection. Those 44 patients were all nonimmunosuppressed patients and did not receive antimycobacterial treatment. Demographic characteristics and distribution of clinical infections are shown in Table 1. The mean age was 50.81 ± 21.03 years. Fifty-seven

Table 1. Demographic and Clinical Characteristics of Patients With *Mycobacterium abscessus* Complex Infection (n = 108)

Characteristic	n = 108 (%)
Age, mean \pm SD, y	50.81 \pm 21.03
Gender	
Male	52 (47.2)
Female	57 (52.8)
Ethnicity	
Hispanic	41 (38.0)
Caucasian	34 (31.5)
African American	27 (25.0)
Other	6 (5.5)
Site of <i>M. abscessus</i> complex infection	
Respiratory	59 (54.6)
Blood	21 (19.4)
Skin and soft tissue	10 (9.2)
Abdominal	9 (8.3)
Bone	6 (5.6)
Disseminated	3 (2.8)
Related comorbidities	
Cystic fibrosis	9 (8.3)
HIV	17 (15.6)
COPD	18 (16.5)
Interstitial lung disease	5 (4.6)
Chronic bronchiectasis	12 (10.9)
Diabetes mellitus	17 (15.6)
Organ transplant	20 (18.5)
Kidney	5 (4.6)
Liver	4 (3.7)
Lung	5 (4.6)
Heart	1 (0.9)
Multivisceral	3 (2.8)
Allogeneic bone marrow	2 (1.9)
Active malignancy	17 (15.6)
Inflammatory autoimmune disease	6 (5.6)
Liver cirrhosis	6 (5.6)
Gastroesophageal reflux disease	9 (8.3)
Immunosuppressive therapy in the last 3 mo	34 (31.5)
Prednisone	5 (4.6)
Prednisone + tacrolimus	3 (2.8)
Prednisone + mycophenolic acid + tacrolimus	19 (16.1)
Azathioprine	2 (1.9)
Prednisone + tacrolimus + antithymoglobulin	4 (3.7)
Anti-tumor necrosis factor agent	1 (0.9)

Abbreviation: COPD, chronic obstructive pulmonary disease.

(52.8%) were females, and 41 (38%) were Hispanics. Eleven (10.2%) of the patients had end-stage renal disease, 34 (40%) were on immunosuppressive therapy, and 40% had chronic lung disease including cystic fibrosis, chronic obstructive pulmonary disease, etc. Fifty-nine organisms (54.6%) were isolated in respiratory cultures, 21 (19.4%) in blood, 10 (9.2%) skin and soft tissue, and 9 (8.3%) intra-abdominal/peritoneal fluid. Antimicrobial susceptibility reports were available for 64 (59.3%) of the patients (Table 2). Clarithromycin, amikacin, and tigecycline were among the most active antimicrobial agents against our isolates (93.8%, 93.8%, and 89.1%, respectively). None of the isolates were susceptible to trimethoprim/sulfamethoxazole, and only 1 isolate was susceptible to ciprofloxacin. Only 44% were susceptible to linezolid and 12% to doxycycline (Table 2). Fewer isolates were tested for clofazimine (n = 31), kanamycin (n = 36), doxycycline (n = 56), and azithromycin (n = 44). The susceptibilities to kanamycin and azithromycin were 100% and 95.5%, respectively (Table 2). Seventy-five patients received antibiotics active against *M. abscessus*, with 28 of those 75 containing at least 1 intravenous agent (Table 3).

Thirty-six (33.3%) patients early failed treatment based on our study criteria; of those, 17 (15.7%) died while hospitalized. On bivariate analysis (Table 4), clarithromycin resistance ($P < .001$), intravenous amikacin treatment ($P = .04$), acute kidney injury ($P = .001$), dialysis ($P = .001$), solid organ transplant ($P = .005$), disseminated infection ($P = .04$), immunosuppressive therapy ($P = .04$), central line ($P = .015$), and presence of prosthetic devices ($P = .04$) were the risk factors significantly associated with treatment failure. On the other hand, receiving treatment with macrolide was found to be significantly associated with lower early treatment failure, with a P value of .04.

On subsequent multivariate analyses (Table 4), the following variables were significant risk factors for early treatment failure: clarithromycin resistance (odds ratio [OR], 79.5; 95% confidence interval [CI], 6.2–3717.1; $P < .001$), intravenous amikacin treatment (OR, 4.1; 95% CI, 0.9–21; $P = .04$), disseminated infection (OR, 11.79; 95% CI, 1.53–81.69; $P = .04$), acute kidney injury (OR, 6.55; 95% CI, 2.4–31.25; $P = .018$), presence of prosthetic device (OR, 5.43; 95% CI, 1.57–18.81; $P = .008$), immunosuppressive therapy (OR, 2.81; 95% CI, 1.6–21.4; $P = .002$), and organ transplantation (OR, 2.37; 95% CI, 2.7–23.1; $P = .005$). Treatment with macrolide was found to be protective against early treatment failure (OR, 0.13; 95% CI, 0.002–1.8; $P = .04$).

A subgroup bivariate analysis was conducted for the patients who had respiratory infections showing a significant correlation between early treatment failure and the following risk factors: macrolide treatment receipt ($P = .01$), multiple sites of infection ($P = .04$), prosthetic device ($P < .001$), COPD ($P = .03$), and acute kidney injury ($P = .04$) (Table 5). After adjustment for confounders in the multivariate analysis, the presence of prosthetic device (OR, 8.1; 95% CI, 2.3–33; $P < .001$), macrolide treatment (OR, 0.14; 95% CI, 0.01–0.5; $P = .2$), acute kidney

Table 2. Antimicrobial Susceptibility (In Vitro) *Mycobacterium abscessus* Group (n = 64)

Antimicrobial Agent	Susceptible MIC, µg/mL, No. (%)	Intermediate MIC, µg/mL, No. (%)	Resistant MIC, µg/mL, No. (%)
Amikacin	≤16, 60 (93.8)	32, 4 (6.2)	≥64, 0 (0)
Amoxicillin/clavulanic acid	≤8/4, 0 (0)	16/8, 5 (12.2)	≥32/16, 36 (87.8)
Azithromycin ^a	≤128, 42 (95.5)	256, 0 (0)	≥512, 2 (4.5)
Cefoxitin	≤16, 22 (34.4)	32–64, 39 (60.9)	≥128, 3 (4.7)
Ciprofloxacin	≤1, 1 (1.6)	2, 0 (0)	≥4, 63 (98.4)
Clarithromycin	≤2, 60 (93.8)	4, 0 (0)	≥8, 4 (6.2)
Clofazimine ^b	≤1, 51 (100)	2, 0 (0)	≥4, 0 (0)
Doxycycline ^c	≤1, 7 (12.3)	8, 0 (0)	≥16, 50 (87.7)
Imipenem	≤4, 22 (34.4)	8, 33 (51.5)	≥16, 9 (14.1)
Kanamycin ^d	≤16, 36 (100)	32, 0 (0)	≥64, 0 (0)
Linezolid	≤8, 28 (43.8)	16, 13 (20.3)	≥32, 23 (35.9)
Moxifloxacin	≤1, 4 (6.2)	2, 0 (0)	≥4, 60 (93.8)
Tigecycline	≤2, 57 (89.1)	4, 3 (4.7)	>4, 4 (6.2)
Tobramycin	≤4, 32 (50)	8, 4 (6.2)	≥16, 28 (43.8)
Trimethoprim/sulfamethoxazole	≤32, 0 (0)	NA, 0 (0)	≥64, 64 (100)

Abbreviations: MIC, minimum inhibitory concentration; NA, not available. ^aForty-four were tested for azithromycin sensitivity.

^bFifty-one isolates tested for clofazimine susceptibility.

^cFifty-seven isolates were tested for doxycycline sensitivity.

^dThirty-six isolates only were tested for kanamycin sensitivity.

injury (OR, 3.4; 95% CI, 0.9–18; $P = .04$), and COPD (OR, 3.1; 95% CI, 1.04–10.8; $P = .04$) showed significant association with treatment failure (Table 5).

DISCUSSION

Our study describes the short-term outcomes of a large cohort of hospitalized patients with *M. abscessus* complex infections in Miami, Florida, and differs from previous studies analyzing long-term outcomes such as treatment failure among outpatients with *M. abscessus* complex infections [13–15]. To our knowledge, this is the largest case series of *M. abscessus* complex infections over a 4-year period described in the literature.

Thus far, *M. abscessus* complex has been considered the most pathogenic of the rapidly growing mycobacteria, accounting for approximately 65% to 80% of lung disease caused by such, and most likely to cause pulmonary infections in patients with underlying lung disease such as cystic fibrosis [1–3, 16–21]. In our study, the most frequent source of *M. abscessus* complex infections was respiratory (57.4%), similar to previous studies [1–3, 16, 17]. *M. abscessus* complex is known to cause infections in immunocompromised hosts [22–26]. Redelman-Sidi et al. reported 44 cases of *M. abscessus* complex over a 10-year period at a large cancer center in New York [22]; Candido et al. reported 30/129 patients with cystic fibrosis with NTM pulmonary infections over a 4-year period in Brazil [23]. Longworth et al. recently reported 15 cases of *M. abscessus* out of 34 (44%) NTB infections in solid organ transplant recipients over a 7.5-year period [24], and Knoll et al. reported 5/53 (9.4%) cases of *M. abscessus* complex in 53 transplant recipient patients who had 1 or more cultures positive for NTM over 15 years [25]. Smaller cases series of *M. abscessus* complex have

been reported by others [26–28]. In our cohort, 20/108 (19%) patients were solid organ transplant recipients (kidney, lung, and liver being the most common); 34 (31.5%) patients were on immunosuppressive therapy. However, organ transplant was not associated with treatment failure among the patients with respiratory infections, which could be due to the small number of patients included in our cohort.

Our study identified a high rate of early treatment failure among hospitalized patients who developed infections with *M. abscessus* group strains. Risk factors highly associated with early treatment failure were presence of disseminated infection, resistance to clarithromycin, intravenous amikacin treatment receipt, acute kidney injury, and prosthetic device, followed by prior transplantation and immunosuppressive therapy use. The significant treatment failure associated with clarithromycin resistance is concordant with other publications. Park et al. demonstrated higher disease progression and worse treatment outcome in pulmonary *M. abscessus* isolates that harbored the erythromycin ribosome methyltransferase (*erm*) (41) gene [13]. Koh et al. showed that 92% of antibiotic treatment failure defined as recurrence or persistence of positive culture after 12-month treatment for *M. abscessus* pulmonary infections was caused by different *M. abscessus* genotype coinfections [14]. A negative conversion at 12 months of treatment completion was significantly higher in *M. abscessus* isolates of the C28 sequevar, smooth colonies, and those susceptible to clarithromycin [14]. Our subgroup multivariate analysis revealed a significantly lower rate of treatment failure if treated with macrolide (Table 5). The clarithromycin resistance association with treatment failure could not be assessed in this subgroup of patients given that the number of resistant strains to macrolide was low

Table 3. Initial Drug Regimens and Therapy Modifying/Ending Side Effects for Pulmonary and Extrapulmonary Disease During Initial Regimen

Regimen	Pulmonary Disease (n = 36) (%)	Extrapulmonary (n = 72) (%)	Therapy Side Effect (n = 28) (%)	Description of Side Effects (No.)	Outcome, No.
No IV antimicrobial used (n = 47)					
Clarithromycin, linezolid, doxycycline	4 (11.1)	5 (6.9)	3 (10.7)	GI upset (3)	1 patient with <i>M. abscessus</i> bacteremia had microbiological failure so got switched to IV imipenem, IV tigecycline, and oral clarithromycin
Azithromycin, moxifloxacin, inhaled amikacin	3 (8.3)	0 (0)	1 (3.6)	Skin rash (1)	1 patient with <i>M. abscessus</i> pneumonia had radiological failure so got switched to IV imipenem, oral azithromycin, and oral doxycycline
Clarithromycin, linezolid, doxycycline	2 (5.6)	6 (8.3)	2 (7.1)	Thrombocytopenia (2)	2 died
Clarithromycin, linezolid, doxycycline, inhaled amikacin	4 (11.1)	0 (0)	3 (10.7)	GI upset (1), skin rash (1), dyspnea (1)	No treatment failure at week 12
Azithromycin, linezolid, moxifloxacin	4 (11.1)	6 (8.3)	1 (3.6)	Cardiac arrhythmia (1)	2 patients had microbiological failure at week 12 with clinical worsening, so their treatments were changed to IV cefoxitin (for 1 patient and IV imipenem for the second), IV azithromycin, and IV tigecycline
Azithromycin, ethambutol, linezolid, levofloxacin	5 (13.9)	0 (0)	1 (3.6)	Liver toxicity ^a (1)	1 patient died, and 1 patient was switched to azithromycin, minocycline, and levofloxacin after radiological failure
Azithromycin, ethambutol, linezolid	6 (16.7)	2 (2.8)	1 (3.6)	Skin rash (1)	1 patient died
At least 1 IV antimicrobial(s) used (n = 28)					
Amikacin, azithromycin, linezolid	1 (2.8)	2 (2.8)	2 (7.1)	Acute kidney injury (2)	2 patients died
Cefoxitin, linezolid, azithromycin	1 (2.8)	2 (2.8)	1 (3.6)	Skin rash (1)	1 patient had microbiological failure at week 12 with clinical worsening, so his regimen was switched to IV imipenem, IV tigecycline, oral azithromycin, and oral moxifloxacin
Imipenem, linezolid, azithromycin	2 (5.6)	2 (2.8)	1 (3.6)	Thrombocytopenia (1), skin rash (1)	1 patient died
Tigecycline, inhaled amikacin, ethambutol, levofloxacin	3 (8.3)	0 (0)	1 (3.6)	GI upset (1)	1 patient died, and 2 patients had microbiological and radiological failures, so they were switched to azithromycin, IV cefoxitin (1 patient got imipenem instead of cefoxitin), and doxycycline
Amikacin, cefoxitin, azithromycin	1 (2.8)	2 (2.8)	3 (10.7)	Acute kidney injury (3)	2 patients died
Amikacin, imipenem, azithromycin	2 (5.6)	2 (2.8)	3 (10.7)	Acute kidney injury (3)	2 patients died
Cefoxitin, tigecycline, azithromycin	1 (2.8)	3 (4.2)	2 (7.1)	GI upset (2)	1 patient had microbiological failure (persistent bacteremia at week 12), so his antibiotic regimen was changed to imipenem, azithromycin, and clofazimine
Imipenem, tigecycline, azithromycin	1 (2.8)	2 (2.8)	2 (7.1)	GI upset (2)	1 patient had radiologic failure, so the regimen was changed to IV imipenem, IV amikacin, and azithromycin
Cefoxitin, tigecycline, clofazimine, linezolid	0 (0)	1 (1.4)	1 (3.6)	Skin rash (1)	1 patient had microbiological failure (persistent bacteremia at week 12), so his antibiotic regimen was changed to imipenem, tigecycline, azithromycin, and clofazimine

Abbreviations: GI, gastrointestinal; IV, intravenous.

^aLiver toxicity defined by an increase in liver function tests by 3-fold.

among the respiratory infections (2.8%) (Table 5). Despite the high in vitro susceptibility rates of our *M. abscessus* complex isolates to amikacin, treatment with this antibiotic was associated with a statistically significantly higher failure (Table 4). A plausible explanation is that aminoglycoside-induced renal

toxicity was also high in our patients treated with intravenous amikacin (60%) (Table 3).

South Florida was shown to be a highly significant spatial cluster for pulmonary nontuberculous infections in the United States [10]. Possible theories to explain the difference in the number

Table 4. Bivariate and Multivariate Analysis of Risk Factors for Early Failure of Treatment of *Mycobacterium abscessus* Complex Infections

	Early Failure to Treatment (n = 36), No. (%)	No Early Failure to Therapy (n = 72), No. (%)	Bivariate Analysis, OR (95% CI)	Bivariate Analysis, PValue	Multivariate Analysis, OR (95% CI)	Multivariate Analysis, PValue
Age, y				.52		-
18–40	9 (25)	24 (33.3)	Ref.	Ref.		
41–65	14 (38.9)	29 (40.3)	1.3 (0.5–3.5)	.62	1.01 (0.4–2.9)	.67
>65	13 (36.1)	19 (26.4)	1.8 (0.6–5.2)	.26	1.4 (0.5–4.2)	.34
Gender					-	-
Female	20 (55.6)	37 (51.4)	1.18 (0.5–2.9)	.84	0.9 (0.4–2.1)	.78
Male	16 (44.4)	35 (48.6)				
Race				.54		
Caucasian	12 (33.3)	22 (30.6)	Ref.	Ref.		
Hispanic	15 (41.7)	26 (36.1)	1.1 (0.4–2.7)	.9	0.8 (0.5–2)	.81
African American	8 (22.2)	19 (26.4)	0.8 (0.3–2.3)	.64	0.5 (0.2–2.6)	.6
Other	1 (2.8)	5 (6.9)	0.4 (0.04–3.5)	.38	0.3 (0.03–2.9)	.41
Diabetes mellitus	8 (22.2)	9 (12.5)	1.8 (0.6–4.9)	.3	1.6 (0.5–3.9)	.4
Malignancy	7 (19.4)	10 (13.9)	1.4 (0.5–3.9)	.5	-	-
HIV	6 (16.7)	11 (15.3)	1.1 (0.4–3.2)	.8	1.01 (0.4–2.9)	.85
COPD	6 (16.7)	12 (16.7)	1 (0.3–2.9)	1	-	-
Bronchiectasis	5 (16.7)	7 (9.7)	1.4 (0.4–4.8)	.5	-	-
Autoimmune disease	3 (8.3)	3 (4.2)	2 (0.3–10.4)	.4	-	-
Site of positive culture				.51	-	-
Respiratory	13 (36.1)	23 (31.9)	Ref.	Ref.		
Blood	4 (11.1)	9 (12.5)	0.8 (0.2–3)	.72		
Soft tissue	2 (5.6)	8 (11.1)	0.4 (0.08–2.4)	.35		
Bone	1 (2.8)	2 (2.8)	0.9 (0.07–10.7)	.9		
Abdominal	4 (11.1)	2 (2.8)	3.5 (0.6–22)	.17		
Disseminated infection	3 (8.3)	0 (0)	NP	.01 ^a	11.79 (1.53–81.69)	.041 ^a
Organ transplant	12 (33.3)	8 (11.1)	4.1 (1.3–13)	.004 ^a	2.37 (2.7–23.1)	.005 ^a
Within 1 y of the infection	6 (16.7)	4 (5.6)	3.4 (0.7–17.4)	.06	6.48 (0.29–141.5)	.235
After 1 y of <i>M. abscessus</i> infection	6 (16.7)	4 (5.6)			-	-
Immunosuppressive therapy	19 (52.8)	12 (16.7)	5.6 (2–15.2)	.001 ^a	2.81 (1.6–21.4)	.002 ^a
Central line	17 (47.2)	19 (26.4)	2.5 (0.99–6.3)	.03 ^a	4.17 (0.6–24.7)	.116
Line or prosthetic device removal	9 (25)	8 (11.1)	2.75 (0.8–9)	.06	-	-
Received prosthetic device	29 (80.6)	29 (40.3)	6.14 (2.2–18.6)	.001 ^a	5.43 (1.57–18.81)	.008 ^a
Recent surgery (in the past 6 mo)	15 (41.7)	19 (26.4)	1.9 (0.7–5)	.11	-	-
Acute kidney injury	17 (47.2)	9 (12.5)	6.3 (2.2–18.4)	.001 ^a	6.55 (2.4–31.25)	.018 ^a
Chronic kidney disease	4 (11.1)	6 (8.3)	1.4 (0.3–6.4)	.64	-	-
Dialysis	7 (19.4)	1 (1.4)	17.1 (2–782.7)	.001 ^a	6.48 (0.29–141.5)	.235
Abnormal imaging result	19 (52.8)	31 (43.1)	1.4 (0.6–3.6)	.27	-	-
Antibiotic therapy receipt	23 (63.9)	52 (72.2)	0.7 (0.3–1.7)	.51	-	-
Intravenous amikacin treatment receipt	6 (26.1) ^b	4 (7.7) ^b	4.2 (0.86–22.5)	.03 ^a	4.1 (0.9–21)	.04 ^a
Clarithromycin resistance	3 (75) ^c	1 (1.9) ^c	177 (5.4–9404.1)	<.001 ^a	79 (6.2–3717.1)	<.001 ^a
Macrolide treatment receipt	20 (86.9) ^d	51 (98.1) ^d	0.13 (0.002–1.8)	.04 ^a	0.3 (0.01–1.6)	.048 ^a
Infectious diseases consult	23 (63.9)	35 (48.6)	1.9 (0.8–4.7)	.13	-	-
Discontinuation of antibiotics before 4 wk due to side effect	8 (22.2)	20 (27.8)	0.7 (0.3–2.1)	.29	-	-
Received surgical intervention	22 (61.1)	51 (70.8)	0.6 (0.3–1.6)	.34	-	-

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; IV, intravenous; NP, not possible to calculate; OR, odds ratio; Ref, reference group.

^aMeans significant association.

^bSix out of 23 patients who were treated with IV amikacin failed treatment early vs 4 out of 52 patients who did not fail treatment early who received IV amikacin.

^cThree out of 10 total patients who failed treatment among the 64 *M. abscessus* isolates that were tested for antibiotic susceptibility were clarithromycin resistant vs 1 out of 54 patients who did not fail treatment who had clarithromycin-resistant *M. abscessus* complex.

^dTwenty out of 23 patients who failed treatment were treated with macrolide (clarithromycin or azithromycin) vs 51 out of 52 patients who did not fail treatment who were treated with macrolide.

Table 5. Bivariate Subgroup Analysis of Risk Factors for Early Treatment Failure in Patients With *M. abscessus* Complex Respiratory Infections

	Early Failure to Treatment (n = 19), No. (%)	No Early Failure to Therapy (n = 40), No. (%)	Bivariate Analysis, OR (95% CI)	Bivariate Analysis, PValue	Multivariate Analysis, OR (95% CI)	Multivariate Analysis, PValue
Age, y				.72	-	-
18–40	6 (31.6)	11 (27.5)	Ref.	Ref.	-	-
41–65	6 (31.6)	17 (42.5)	0.6 (0.2–2.5)	.5	0.5 (0.2–2.1)	.6
>65	7 (36.8)	12 (30)	1.1 (0.2–4.1)	.9	0.9 (0.2–3.5)	.7
Gender				.71	-	-
Female	9 (47.4)	21 (52.5)	0.8 (0.2–2.4)	.8	0.7 (0.2–2.1)	.7
Male	10 (52.6)	19 (47.5)				
Race				.26	-	-
Caucasian	10 (52.6)	10 (25)	Ref.			
Hispanic	6 (31.6)	17 (42.5)	0.3 (0.1–1.2)	.1	0.2 (0.3–1.5)	.2
African American	2 (10.5)	9 (22.5)	0.2(0.04–1.2)	.09	0.18 (0.1–1.4)	.12
Other	1 (5.3)	4 (10)	0.25 (0.02–2.6)	.2	0.2 (0.08–2.1)	.3
Diabetes mellitus	5	8	1.3 (0.4–4.6)	.4		
Malignancy	4	6	1.4 (0.4–5.6)	.6	1.3 (0.5–4)	.56
HIV	6	8	1.6 (0.5–5.2)	.4	1.4 (0.6–10)	.4
COPD	10	6	3.5 (1.1–11.1)	.03 ^a	3.1 (1.04–10.8)	.04
Cystic fibrosis	5	4	2.6 (0.6–10.9)	.2	2.1 (0.7–9.4)	.24
Bronchiectasis	6	6	2.1 (0.6–7.4)	.2	1.8 (0.7–6.8)	.3
Interstitial lung disease	2	3	1.4 (0.2–9.1)	.7	1.3 (0.3–8.4)	.6
GERD	3	4	1.6 (0.3–7.8)	.6	1.4 (0.5–6.4)	.5
Presence of second site of infection	3 (15.8)	0 (0)	NP	.04 ^a	NP	.05
Organ transplant	5 (26.3)	5 (12.5)	2.5 (0.5–12.6)	.2	-	-
Immunosuppressive therapy	14 (73.7)	24 (60)	1.8 (0.5–7.9)	.2	-	-
Central line	1 (5.3)	3 (7.5)	0.7 (0.02–9.3)	.75	-	-
Line or prosthetic device removal	1 (5.3)	1 (2.5)	2.1 (0.02–165.17)	.6	-	-
Prosthetic device	14 (73.7)	9 (22.5)	9.6 (2.4–42.4)	<.001 ^a	8.1 (2.3–33)	<.001 ^a
Recent surgery	5 (26.3)	6 (15)	2.02 (0.4–9.4)	.3	-	-
AKI	6 (31.6)	4 (10)	4.12 (0.8–22.8)	.04 ^a	3.4 (0.9–18)	.04 ^a
ESRD	1 (5.3)	4 (10)	0.5 (0.01–5.6)	.5	-	-
Dialysis	1 (5.3)	1 (2.5)	2.1 (0.02–165.17)	.6	-	-
Intravenous amikacin treat- ment receipt	3 (7.5)	10 (31.3)	6.6 (0.4–361.8)	.08	5.6 (0.5–268.4)	.08
Clarithromycin resistance	1 (7.7)	0 (0)	NP	.17	-	-
Macrolide treatment receipt	10 (30.3) ^b	3 (100) ^b	0 (0–0.6)	.01 ^a	0.14 (0.01–0.5)	.02 ^a
Antibiotic therapy receipt	13 (68.4)	23 (57.5)	1.6 (0.4–6.2)	.42	-	-
Infectious diseases consult	8 (42.1)	11 (27.5)	1.9 (0.5–6.9)	.26	-	-
Discontinuation of antibiotics	5 (26.3)	15 (37.5)	0.6 (0.1–2.2)	.39	-	-
Treatment measures other than antibiotics	16 (84.2)	36 (90)	0.6 (0.09–4.6)	.52	-	-

Abbreviations: AKI, acute kidney injury; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; NP, not possible to calculate; OR, odds ratio.

^aStatistically significant.

^bTen out of 33 patients with *M. abscessus* complex lung infections who received macrolide had early treatment failure vs 3 patients who did not receive macrolides out of 3 who had early treatment failure.

of infections compared with other regions in the United States include the warm tropical climate and water colonization [9]. *M. abscessus* are organisms that have the ability to survive and proliferate in habitats that they share with humans, such as drinking water [9]. Although chlorine is the most commonly used disinfectant to treat drinking water in the United States [29], it has been reported that the Miami-Dade County Water and Sewer department use monochloramine (<http://www.miamidadegov/water/water-supply-treatment.asp#3>). Most communities use

either chlorine or chloramines and switch back and forth between these products at different times of the year or for operational reasons [29]; there is evidence that bacterial communities shift during water disinfection, and mycobacteria have been found to increase during monochloramine treatment [30]. Furthermore, Donohue et al. showed that there are statistically significant higher levels of NTM in nonchlorinated than in chlorinated tap water [31]. Unlike the *M. abscessus* complex outbreak linked to hospital tap water at a tertiary care hospital in Durham, North

Carolina [32], the characteristics of the identified cases included in our study failed to fulfill the criteria for an outbreak as the number of reported cases yearly has remained almost the same throughout the 4 years of our study at all the sites of infection; our cases were not clustered in a particular area or hospital unit, nor were they related to a specific procedure or patient population.

Other risk factors previously associated with treatment failures or worst outcomes include macrolide resistance through the inducible erm (41) gene, including failure of achieving or maintaining culture conversion [14, 15, 33, 34]. In our study, clarithromycin and amikacin were the most likely antimicrobials to be susceptible in vitro, and all our tested *M. abscessus* isolates for macrolide susceptibility had MICs for clarithromycin determined before and after an extended 2-week incubation with clarithromycin to evaluate the presence of an active erm (41) gene. Our high susceptibility rates to macrolides among our *M. abscessus* isolates could be due to the predominance of *M. abscessus* subsp. *massiliense* in our isolates, which appears to be more susceptible to macrolides than *M. abscessus* sensu stricto and *M. bollettii* [34]. This contrasts with previous studies describing constitutive macrolide resistance between 2.7% and 28.6% and inducible resistance in 65% to 68.8% of *M. abscessus* complex isolates [35–37].

In our study, we found a high proportion of fluoroquinolone resistance, confirming the results of a study by Maurer et al. that evaluated the in vitro activities of all generations of quinolones for clinical and reference rapidly growing mycobacteria and found gyrA and gyrB mutations responsible for an intrinsic low level of resistance to quinolones in mycobacteria [33]. However, other rapidly growing mycobacteria species showed distinct susceptibilities to this class of antimicrobials and patterns of mutations, contrary to what has been traditionally defined, suggesting that other mechanisms of resistance, different from gyrA or gyrB mutations, may also be involved in resistance to high levels of quinolones [38].

Of the isolates tested, more were susceptible to amikacin (93.8%) than any other antibiotic. Some studies suggest that chromosomally encoded drug-modifying enzymes play an important role in the lack of aminoglycoside bactericidal activity against rapidly growing mycobacteria [29], but the clinical significance is unknown. Few studies have evaluated the synergy between 2 antibiotics against *M. abscessus* [39, 40]. The in vitro combination of clofazimine and amikacin shows a significant synergistic activity [41]. A study by Huang et al. in Taiwan reported synergy between tigecycline and clarithromycin but an antagonistic activity between tigecycline and amikacin [39].

Although our study found decreased susceptibilities to imipenem and ceftazidime in vitro, the use of either of those 2 agents remains the backbone of combination treatment of *M. abscessus* group infections. A French study showed that most of the *M. abscessus* isolates were moderately susceptible or intermediately resistant to ceftazidime and imipenem, with the MIC distributions for ceftazidime and imipenem very close to the breakpoints

[40]. Another study showed that *M. abscessus* produces a clavulanate-insensitive broad-spectrum β -lactamase that limits the in vivo efficacy of β -lactams, except ceftazidime and, to a lower limit, imipenem [42]. Epidemiological cutoff values for wild-type strains should be determined to improve the interpretation of MICs for clinical strains. Similarly, studies are warranted to further understand the correlation between the in vitro and the in vivo activity of the antibiotics against these organisms. The paucity of bactericidal antibiotics to treat these organisms in addition to the immune state of the hosts affected by these infections could explain, in some cases, the poor therapeutic outcomes of *M. abscessus* group infections [33].

The strengths of our study include the high number of cases over a 4-year period within 2 hospitals and, to our knowledge, the largest case series to date. The inclusion of multiple sources of infections, a high proportion of immunocompromised and immunocompetent patients, and the comprehensive review of potential risk factors were associated with early treatment failure in *M. abscessus* group infections. Our study also has limitations, including the retrospective design, analysis of a specialized hospitalized population in a single urban area, and the unavailability of subspecies information and molecular typing. Short-term outcome is another limitation to be considered. Our number of deaths is probably underestimated because some patients might have been lost to follow-up. Unfortunately, there is no consensus definition of *M. abscessus* complex infection treatment failure, which is clinically relevant and needed in the near future. In addition, the antimicrobial susceptibilities of *M. abscessus* group are not routinely done locally by our microbiology laboratories but are sent out based upon the treating physician's request; therefore, in vitro synergistic antimicrobial activity against *M. abscessus* group is seldom reported. Nonetheless, we believe our study is an important contribution to the literature relevant to health care providers who encounter infections with nontuberculous mycobacteria worldwide.

In conclusion, *M. abscessus* complex can lead to severe infections with high morbidity and mortality. We describe our experience in Miami, the antimicrobial susceptibility trends and risk factors that correlated with worse outcomes. Future studies are needed to better understand the causes of high prevalence in South Florida and develop efforts to prevent and optimize the management of these multidrug-resistant infections.

Acknowledgments

Financial support. None.

Potential conflicts of interest. None. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; 175:367–416.

2. Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. *Clin Chest Med* **2015**; 36:67–78.
3. Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. *Clin Chest Med* **2002**; 23:623–32, vii.
4. Colombo RE, Olivier KN. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. *Semin Respir Crit Care Med* **2008**; 29:577–88.
5. Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, *Mycobacterium abscessus*, n. sp. *J Invest Dermatol* **1953**; 20:133–69.
6. Schnabel D, Gaines J, Nguyen DB, et al; Centers for Disease Control and Prevention (CDC). Notes from the field: rapidly growing nontuberculous *Mycobacterium* wound infections among medical tourists undergoing cosmetic surgeries in the Dominican Republic—multiple states, March 2013–February 2014. *MMWR Morb Mortal Wkly Rep* **2014**; 63:201–2.
7. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* **2007**; 175:367–416.
8. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmenting rapidly growing mycobacteria. *Clin Microbiol Rev* **2002**; 15:716–46.
9. Falkinham JO. The changing pattern of nontuberculous mycobacterial disease. *Can J Infect Dis* **2003**; 14:281–6.
10. Adjemian J, Olivier KN, Seitz AE, et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. *Am J Respir Crit Care Med* **2012**; 186:553–8.
11. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* **2004**; 8:204–12.
12. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M-100*. 24th ed. Wayne, PA: CLSI; **2014**.
13. Park J, Cho J, Lee CH, et al. Progression and treatment outcomes of lung disease caused by *Mycobacterium abscessus* and *Mycobacterium massiliense*. *Clin Infect Dis* **2017**; 64:301–8.
14. Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial characteristics and treatment outcomes in *Mycobacterium abscessus* lung disease. *Clin Infect Dis* **2017**; 64:309–16.
15. Tung YJ, Bittaye SO, Tsai JR, et al. Risk factors for microbiologic failure among Taiwanese adults with *Mycobacterium abscessus* complex pulmonary disease. *J Microbiol Immunol Infect* **2015**; 48:437–45.
16. Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to *Mycobacterium abscessus* complex. *Int J Tuberc Lung Dis* **2014**; 18:1141–8.
17. Benwill JL, Wallace RJ Jr. *Mycobacterium abscessus*: challenges in diagnosis and treatment. *Curr Opin Infect Dis* **2014**; 27:506–10.
18. Wallace RJ Jr, Swenson JM, Silcox VA, et al. Spectrum of disease due to rapidly growing mycobacteria. *Rev Infect Dis* **1983**; 5:657–79.
19. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. *Am Rev Respir Dis* **1993**; 147:1271–8.
20. Chan ED, Kaminska AM, Gill W, et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits *Mycobacterium abscessus* infection of macrophages. *Scand J Infect Dis* **2007**; 39:690–6.
21. Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. *Am J Clin Pathol* **2007**; 128:612–21.
22. Redelman-Sidi G, Sepkowitz KA. Rapidly growing mycobacteria infection in patients with cancer. *Clin Infect Dis* **2010**; 51:422–34.
23. Cândido PH, Nunes Lde S, Marques EA, et al. Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients. *J Clin Microbiol* **2014**; 52:2990–7.
24. Longworth SA, Vinnard C, Lee I, et al. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. *Transpl Infect Dis* **2014**; 16:76–83.
25. Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. *Transpl Infect Dis* **2012**; 14:452–60.
26. El Helou G, Hachem R, Viola GM, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients. *Clin Infect Dis* **2013**; 56:843–6.
27. Shields RK, Clancy CJ, Mince LR, et al. Epidemiology and outcomes of deep surgical site infections following lung transplantation. *Am J Transplant* **2013**; 13:2137–45.
28. Wentworth AB, Drage LA, Wengenack NL, et al. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study. *Mayo Clin Proc* **2013**; 88:38–45.
29. National Sanitation Foundation (NSF) website. <http://info.nsf.org/Certified/DWTFU/Listings.asp?PlantState=TX&PlantCountry=UNITED+STATES&hd-ModStd=ModStd>. Accessed 10 March 2016.
30. Chiao TH, Clancy TM, Pinto A, et al. Differential resistance of drinking water bacterial populations to monochloramine disinfection. *Environ Sci Technol* **2014**; 48:4038–47.
31. Donohue MJ, Mistry JH, Donohue JM, et al. Increased frequency of nontuberculous *Mycobacterium* detection at potable water taps within the United States. *Environ Sci Technol* **2015**; 49:6127–33.
32. Baker AW, Lewis SS, Alexander BD, et al. Two-phase hospital-associated outbreak of *Mycobacterium abscessus*: investigation and mitigation. *Clin Infect Dis* **2017**; 64:902–11.
33. Maurer FP, Bruderer VL, Ritter C, et al. Lack of antimicrobial bactericidal activity in *Mycobacterium abscessus*. *Antimicrob Agents Chemother* **2014**; 58:3828–36.
34. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the *Mycobacterium abscessus* group by erm(41) and rrl sequencing. *Antimicrob Agents Chemother* **2011**; 55:775–81.
35. Lee SH, Yoo HK, Kim SH, et al. Detection and assessment of clarithromycin inducible resistant strains among Korean *Mycobacterium abscessus* clinical strains: PCR methods. *J Clin Lab Anal* **2014**; 6: 1–6.
36. Yoshida S, Tsuyuguchi K, Suzuki K, et al. Further isolation of *Mycobacterium abscessus* subsp. *abscessus* and subsp. *bolletii* in different regions of Japan and susceptibility of these isolates to antimicrobial agents. *Int J Antimicrob Agents* **2013**; 42:226–31.
37. Rubio M, March F, Garrigó M, et al. Inducible and acquired clarithromycin resistance in the *Mycobacterium abscessus* Complex. *PLoS One* **2015**; 10:e0140166.
38. de Moura VC, da Silva MG, Gomes KM, et al. Phenotypic and molecular characterization of quinolone resistance in *Mycobacterium abscessus* subsp. *bolletii* recovered from postsurgical infections. *J Med Microbiol* **2012**; 61:115–25.
39. Huang CW, Chen JH, Hu ST, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. *Int J Antimicrob Agents* **2013**; 41:218–23.
40. Lavollay M, Dubée V, Heym B, et al. In vitro activity of cefoxitin and imipenem against *Mycobacterium abscessus* complex. *Clin Microbiol Infect* **2014**; 20:O297–300.
41. van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. *Antimicrob Agents Chemother* **2012**; 56:6324–7.
42. Soroka D, Dubée V, Soulier-Escrihuela O, et al. Characterization of broad-spectrum *Mycobacterium abscessus* class A β -lactamase. *J Antimicrob Chemother* **2014**; 69:691–6.